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Abstract
Zika virus (ZIKV) belongs to the positive-sense single-stranded RNA-containing Flaviviridae family. Its recent outbreak 
and association with human diseases (e.g. neurological disorders) have raised global health concerns, and an urgency to 
develop a therapeutic strategy against ZIKV infection. However, there is no currently approved antiviral against ZIKV. Here 
we present a comprehensive overview on recent progress in structure–function investigation of ZIKV NS5 protein, the largest 
non-structural protein of ZIKV, which is responsible for replication of the viral genome, RNA capping and suppression of 
host interferon responses. Structural comparison of the N-terminal methyltransferase domain and C-terminal RNA-dependent 
RNA polymerase domain of ZIKV NS5 with their counterparts from related viruses provides mechanistic insights into ZIKV 
NS5-mediated RNA replication, and identifies residues critical for its enzymatic activities. Finally, a collection of recently 
identified small molecule inhibitors against ZIKV NS5 or its closely related flavivirus homologues are also discussed.
Keywords Viral replication · Flavivirus · Non-structural protein 5 · RNA capping · Pathogen–host interaction · Drug 
discovery · Antiviral inhibitors
Introduction
Viruses of the Flaviviridae family are widespread vector-
borne pathogens, causing large epidemics and tens of thou-
sands of deaths every year. The family is comprised of three 
genera—Pestivirus, Hepacivirus, and Flavivirus—with over 
70 viruses, including the human pathogens dengue virus 
(DENV), yellow fever virus (YFV), West Nile virus (WNV), 
tick-borne encephalitis virus (TBEV), Japanese encephalitis 
virus (JEV), hepatitis C virus (HCV), and Zika virus (ZIKV) 
[1]. ZIKV emerged as a major global pathogen after large 
outbreaks occurred in Micronesia (2007), French Polynesia 
(2013), and Brazil (2015). In response to the accelerated 
global transmission of ZIKV, the World Health Organization 
(WHO) declared a public health emergency of international 
concern [2, 3]. In addition to its rapid transmission, these 
outbreaks have been associated with severe neurological 
disorders such as microcephaly [4] and Guillain–Barré syn-
drome (GBS) [5].
Like other flaviviruses, ZIKV is a small, enveloped virus 
with non-segmented ~ 10–12 kb single-stranded positive-
sense RNA genome that is capped at the 5′ end, and lacks a 
3′ polyA tail. ZIKV enters host cells via receptor-mediated 
endocytosis [6], with AXL, a gene that encodes a receptor 
tyrosine kinase, as a candidate receptor [7, 8]. The range of 
permissible cell types and the host-cell receptors that medi-
ate ZIKV entry are still being investigated. Recent in vitro 
studies have shown that AXL and other receptors in the 
TYRO3-ALXL-MERTK (TAM) family permit ZIKV entry 
in human skin cells [9] and that AXL is highly expressed in 
developing human cerebral cortexes [8]. However, deletion 
of TAM receptors in mice does not reduce ZIKV replication 
in vivo, suggesting that these receptors may not play a role 
in ZIKV infection, or that several redundant entry receptors 
exist for ZIKV [10, 11]. Following endocytosis, the enve-
lope protein undergoes a low pH-dependent conformational 
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change that results in fusion of the viral membrane with 
the host membrane, leading to release of the capsid-bound 
genome (nucleocapsid) into the cytoplasm [12]. The genome 
is then dissociated from the capsid, translated as a single 
polyprotein, and replicated within endoplasmic reticulum 
(ER)-derived vesicle packets. The polyprotein is co- and 
post-translationally cleaved by both viral and host proteases 
to generate three structural (capsid, pre-membrane, and 
envelope) and seven non-structural (NS1, NS2A, NS2B, 
NS3, NS4A, NS4B, and NS5) proteins [13].
Immature virions are assembled in the lumen of the ER 
and trafficked to the Golgi apparatus where select proteins 
are modified by glycosylation (Fig. 1) [14, 15]. Subsequent 
maturation of virions occurs through proteolytic cleav-
age of prM by a yet unknown host furin-like protease and 
homodimerization of the envelope protein in the trans-Golgi 
network [16, 17]. In addition to mature infectious viral parti-
cles, this process generates non-infectious subviral particles, 
which lack the capsid protein and the RNA genome. Both 
mature infectious viral progeny and subviral particles are 
released from the host cells through exocytosis (Fig. 1).
The role of ZIKV NS5 in viral replication 
and virus–host interaction
The viral NS5 protein is the largest (~ 100 kDa) and most 
conserved ZIKV protein, with 94% sequence identity 
between the two major ZIKV lineages: Asian and African 
[3]. NS5 is comprised of two domains, an N-terminal meth-
yltransferase domain and an RNA-dependent RNA poly-
merase (RdRP) domain at the C-terminal end [18–20]. It 
performs three essential roles in the viral life cycle: genome 
replication [21, 22] and capping [23], and interferon sup-
pression [24, 25] (Fig. 2). In addition, recent evidence sug-
gested that it might also play a role in modulating the activ-
ity of cellular spliceosome [26].
Genome replication
The RdRP domain of ZIKV NS5 (NS5-RdRP), like its coun-
terparts in other members of Flaviviridae family, generates 
positive- and negative-sense copies of the RNA genome via 
a de novo mechanism [27–29], that is, it uses RNA as a tem-
plate but does not require a primer to elongate nascent RNA. 
Fig. 1  Schematic view of the ZIKV replication cycle. The replication 
cycle of ZIKV is similar to other known flaviviruses. Its E proteins 
are involved in the attachment of the virus to receptors on the host 
membrane. Subsequently, the virus enters the cell via endocytosis. 
Viral genomic RNA is released into cytoplasm after fusion of viral 
and host membranes. The single-stranded RNA (ssRNA) is first trans-
lated to a polyprotein, which is then cleaved into several viral pro-
teins. Viral genomes replicate on the endoplasmic reticulum (ER) 
surface. After assembly at the ER, the virus buds with the help of 
the host ESCRT (endosomal sorting complexes required for trans-
port) machinery. Through Golgi apparatus, its prM protein is cleaved, 
which indicates the maturation of virions. Finally, the ZIKV exits the 
cell via exocytosis
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The NS5-RdRP-mediated replication process is thought to 
involve three distinct conformational states [27, 30–32]. In 
the first state, pre-initiation, NS5 is poised to receive ini-
tial NTPs, but the RNA exit tunnel is blocked. In the sec-
ond state, initiation, the secondary structure of the 3′ and 
5′ untranslated regions (UTRs) and the cyclization of the 
genome permit NS5 to bind to the 3′ end of the viral RNA 
template. Meanwhile, ATP and GTP molecules enter the 
active site of NS5-RdRP to form Watson–Crick pairs with 
the conserved C and U bases at the 3′ end of the viral tem-
plate RNA. Subsequently, a ribose–phosphate bond is gener-
ated by nucleophilic attack by the activated alcohol group of 
the adenine ribose on the guanine α-phosphate. These two 
nucleotides serve as the initial dinucleotide primer [33]. In 
the third state, elongation, the RNA exit tunnel of NS5 opens 
up, ensuring processive RNA polymerization. It is likely 
that additional viral factors are also involved in facilitating 
ZIKV RNA replication, as observed in other flaviviruses. 
For example, ZIKV NS3 encodes a helicase domain, which 
is essential to unwind the double-stranded (ds) RNA inter-
mediate formed during genome synthesis [34–38]. Addi-
tionally, the NS4B protein was reported to be involved in 
membrane alterations and anchoring of the viral replication 
complex on the cellular membrane [39].
Capping
The methyltransferase activity possessed by the N-terminal 
methyltransferase (MTase) domain of NS5 is required for the 
final steps in generating the type-I 5′ cap using S-adenosyl-
methionine (SAM) as the methyl donor [40–42]. Based on 
in vitro evidence, the MTase domain mediates methylation 
of the N7 atom of the cap guanine (G0) and the 2′-O atom of 
the adenine ribose (the first nucleotide of the viral genome) 
through a two-step reaction [41]. In addition, the N-termi-
nal MTase serves as a guanylyltransferase [41], which uses 
GTP as a substrate to form a covalent NS5–GMP intermedi-
ate, followed by transfer of the GMP from NS5 to the end 
of an acceptor RNA transcript. Notably, formation of the 
NS5–GMP intermediate can be stimulated by the NS3 heli-
case [41].
Interferon suppression
Type I interferons (IFN-α and -β) play a critical role in 
controlling viral infection [43–46]. To establish infection, 
flaviviruses have developed various immune evasion mecha-
nisms to suppress the type I IFN antiviral responses [47–55]. 
Of particular note, both the DENV and ZIKV NS5 proteins 
inhibit the type I interferon responses by binding the host 
signal transducer and activator of transcription 2 (STAT2) 
and targeting it for proteasome-dependent degradation [49, 
54–56]. DENV NS5 also interacts with the host E3 ubiq-
uitin-protein ligase (UBR4), a component of the host pro-
teasome that is required for DENV NS5-mediated STAT2 
degradation [55]. In addition to recruiting UBR4, the DENV 
NS5 protein must be matured proteolytically at its N termi-
nus for STAT2 degradation to occur [56]. Domain mapping 
revealed that the first ten amino acids of DENV NS5 are 
required for STAT2 degradation, but not for STAT2 binding 
[56], consistent with the fact that these residues are essen-
tial for UBR4 interaction [55]. The STAT2-binding site of 
DENV NS5 is suggested to be located in the region between 
the MTase and RdRP domains [55, 56]. However, the exact 
amino acids required for STAT2 interaction have yet to be 
elucidated. In contrast to DENV, N-terminal proteolytic 
Fig. 2  The activity of ZIKV 
NS5 in host cells. On the ER 
surface, ZIKV NS5 forms a 
replication complex with other 
non-structural proteins of ZIKV 
(e.g., NS3 and NS4A) to medi-
ate viral replication [18–20]. In 
the cytoplasm, through interac-
tion with STAT2 and a yet 
unknown E3 ubiquitin ligase, 
ZIKV NS5 promotes proteas-
ome-mediated protein degrada-
tion of human STAT2. It has 
been observed that a significant 
amount of ZIKV NS5 enters 
the nucleus, likely affecting the 
function of nuclear receptors or 
other nuclear activities
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processing of ZIKV NS5 is not required for STAT2 deg-
radation, and, while it has been demonstrated that ZIKV 
NS5-mediated STAT2 degradation is proteasome depend-
ent, it is not UBR4 dependent, and the precise component 
of the proteasome involved in ZIKV NS5-mediated STAT2 
degradation has not been identified [49]. These observations 
indicate that ZIKV NS5 uses a mechanism distinct from that 
of DENV NS5 to degrade STAT2. Resolution of the ZIKV 
NS5–STAT2 interaction at the amino acid level, and the 
identification of the required host proteasome component, 
will contribute to the elucidation of the unique degradation 
mechanism employed by ZIKV NS5. This knowledge will 
also make it possible to generate an attenuated ZIKV strain 
for use in a vaccine that is unable to inhibit the host antiviral 
response, and may contribute to the development of antiviral 
therapeutics that target the NS5 protein.
Structural study of ZIKV NS5
Overall structure of ZIKV NS5
Recent evidence has led to the notion that the tandem organi-
zation of the MTase and RdRP subdomains of the flavivi-
rus NS5 facilitates its sequential, RNA-templated activities 
[57, 58]. In particular, the presence of the MTase domain 
enhances the binding affinity of NS5 for RNA template and 
incoming nucleotides, thereby promoting the RdRP-medi-
ated replication initiation and elongation [58]. However, the 
mechanism by which the two subdomains cooperate in RNA 
replication or capping remains undetermined. Nevertheless, 
the crystal structures of full-length NS5 from JEV [57], 
DENV3 [59] and ZIKV [18–20] have recently been deter-
mined, providing direct insights into the domain orientation 
of flavivirus NS5. The crystal structure of ZIKV NS5 reveals 
that the N-terminal MTase domain and C-terminal RdRP 
domain stack against each other, resulting in a buried surface 
area of 1400 Å2. Remarkably, this conformational state of 
ZIKV NS5 shows high resemblance with that of JEV NS5 
(Fig. 3a), superposition of which gives a root-mean-square 
deviation (RMSD) of 0.63 Å over 872 Cα atoms, suggest-
ing that the conformation of NS5 is conserved within the 
Flavivirus genus. Consistent with this suggestion, the amino 
acid residues at the domain interfaces are highly conserved 
(Fig. 3b), including a sequence motif (motif F, see below) 
that likely engages in recognition of template RNA as well 
as incoming NTPs [32]. In contrast, in the crystal structures 
of RdRP alone, this motif either becomes disordered [60, 
61] or adopts different conformation [20], implying that its 
function is modulated by the inter-domain contact. On the 
other hand, the domain orientation of ZIKV NS5 differs 
significantly from that of DENV3 NS5 (Fig. 3a), despite 
that the individual domains superimpose well between the 
two proteins. The MTase domain of DENV3 NS5 interacts 
with the C-terminal RdRP domain through a distinct inter-
face (Fig. 3a), resulting in a less extended conformation 
and an RMSD of 6.06 Å over 844 Cα atoms when super-
imposed with ZIKV NS5. Intriguingly, the residues at the 
domain interface of DENV3 NS5 are also highly conserved 
(Fig. 3b), suggesting functional relevance of this alterna-
tive conformation. The existence of multiple conformations 
of flavivirus NS5 is consistent with previous small angle 
X-ray scattering analysis of DENV3 NS5, which indicates 
the presence of a conformational ensemble of flavivirus 
NS5 in solution [62]. In support of this notion, mutating the 
evolutionarily conserved residues at the domain interface 
resulted in enhanced RdRP activity of DENV3 NS5, but 
impaired viral replication and infectivity, implying that the 
conformational dynamics of NS5 may regulate its activity 
in viral replication [59]. The exact functional implication of 
these alternative conformations awaits future biochemical 
and cellular investigations.
Structure of the ZIKV NS5 MTase domain
As described above, the MTase domain of flavivirus NS5 
mediates the formation of type-1 RNA cap at the 5′-end of 
the nascent +RNA strand, involving a guanylyltransferase 
reaction that transfers GMP to the 5′-end of viral RNA, and 
two MTase reactions that methylate the G0 residue at N7 
position (cap-0) and the 2′-O of A1 (cap-1) [63] (Fig. 4a). 
Capping of the viral RNA is essential for maintaining sta-
bility, and increases viral polyprotein translation efficiency 
[64]. The structures of the MTase domain of ZIKV NS5 [60, 
65–68], similar to what was observed for the other flavivirus 
NS5s [69], reveal a dominant Rossmann fold comprised of 
a seven-stranded β-sheet sandwiched by two α-helices from 
one side and another α-helix from the other side, harboring 
a single binding site for cofactor SAM (Fig. 4b). In addition, 
two appendages from the N- and C-terminal ends join to 
the Rossmann fold, together forming the substrate-binding 
sites (Fig. 4b–d). Structural superposition of the ZIKV NS5 
MTase bound to both m7Gpp and SAM with the DENV3 
MTase bound to cofactor byproduct S-adenosyl-homocyst-
eine (SAH) and m7G0pppAG-RNA revealed well-aligned 
interaction sites for SAM, m7Gpp, and the 2′-O group of 
A1 (Fig. 4e), suggesting that the MTase domain maintains 
a pre-configured conformation for enzymatic catalysis. The 
SAH-binding site of ZIKV NS5–MTase involves residues 
T104–E111 and D131–V132, which interact with the adeno-
sine moiety, and residues S56, K61, R84–W98, I145–D146, 
K182 and E218 that make contacts with the homocysteine 
group (Fig.  4f). On the other hand, binding of m7Gpp 
mainly involves residues in the N-appendage, in which resi-
dues L16, M18, A21, F24 and K28 form a hydrophobic cave 
harboring the guanylyl ring, while residues K13, N17, K28, 
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S150, R213 and S215 interact with the diphosphate group 
or the sugar ring through direct or water-mediated hydrogen 
bonds (Fig. 4g). These co-factor- and substrate-binding sites 
together define the druggable sites within ZIKV NS5.
Structure of the ZIKV NS5‑RdRP domain
The flavivirus genome is strictly conserved with end 
sequences 5′-AG…CU-3′ [32]. Accordingly, the NS5-RdRP 
domain-mediated RNA replication always starts with syn-
thesis of a pppAG dinucleotide [32]. Like with other viral 
RdRPs, flavivirus NS5-RdRP is comprised of Thumb, Palm 
and Fingers subdomains (Fig. 5a, b). Whereas the mecha-
nism by which flavivirus NS5 initiates and elongates the 
RNA substrates remains poorly understood, recent evidence 
has suggested that these processes are regulated by vari-
ous protein and RNA elements (e.g., stem loops at the 5′- 
and 3′-ends), to achieve virus-specific replication [70]. In 
accordance with these regulations, flavivirus NS5-RdRP 
contains a more compact active site, with narrow NTP- and 
RNA template-channels [71], in comparison with the RNA 
polymerases mediating primer-based RNA replication. For 
instance, structural studies of ϕ6 [72, 73], HCV [74, 75] and 
JEV [76] RdRPs have revealed that a loop protruding from 
the Thumb domain, termed priming loop, reaches out to the 
active site to stabilize the formation of a replication pre-
initiation complex, while blocking the RNA exit channel. 
Subsequent transition from initiation state to elongation state 
led to a conformational transition of this loop [74], thereby 
allowing the RNA product to exit from the RdRP molecule. 
Given that the priming loop also exists within ZIKV NS5-
RdRP [3], it is conceivable ZIKV NS5-RdRP employs a 
similar regulatory mechanism during the transition from the 
replication initiation stage to elongation stage [70, 71]. As 
illustrated in Fig. 5a, ZIKV NS5–RdRP-mediated RNA rep-
lication may start with a pre-initiation complex, in which the 
RdRP binds to ATP and GTP, the first two incoming nucleo-
tides of RNA replication (Fig. 5a) [27, 76–79]. Next, a pair 
Fig. 3  Structural comparison of full-length ZIKV NS5, JEV NS5 and 
DENV3 NS5. a Structural overview of ZIKV NS5 (light pink and 
wheat), JEV NS5 (green and light green) and DNEV3 NS5 (aqua-
marine and light blue) under transparent surface. The domain linkers 
are colored in red. The bound SAH molecules are shown in sphere 
representation. b The residues located at the two alternative domain 
interfaces, marked by asterisks, are conserved throughout evolution. 
Identical residues are labeled in white and highlighted in red. Similar 
residues are labeled in red
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of divalent cations  (Mn2+ or  Mg2+) coordinates these initial 
nucleotides with the RdRP molecule to promote the synthe-
sis of the 5′-AG-3′ dinucleotide, resulting in the initiation 
state of replication. Subsequent synthesis of longer RNA 
product leads to opening up of the RNA exit tunnel, allow-
ing the RdRP to enter into the elongation state, in which the 
synthesized RNA processively elongates from the active site 
(Fig. 5a).
The crystal structures of ZIKV NS5–RdRP, either in the 
isolated state [20, 60, 61] or in the context of full-length NS5 
[18–20], have recently been determined. Similar to other 
viral RdRPs [71], the ZIKV NS5-RdRP adopts a capped 
right-hand fold that is further divided into the Palm, Fingers 
and Thumb subdomains (Fig. 5b), each of which harbors 
conserved motifs controlling RNA synthesis [70]. In addi-
tion, an N-terminal extension associates with the Fingers 
subdomain for potential functional regulation (Fig. 5b). The 
Palm subdomain serves as the catalytic center of the RdRP, 
containing conserved motifs with catalytic aspartic acids 
(motifs A and C) [77], mediating template binding, translo-
cation and/or NTP specificity (motif B) [80, 81], nucleotide 
transfer (motif D) [80], and alignment of priming nucleotide 
ATP (motif E) (Fig. 5c) [77]. The Thumb subdomain pre-
sents the priming loop (Fig. 5b) that presumably promotes 
ATP-specific RNA initiation, as well as regulates the sub-
sequent transition to the elongation phase [32]. The Fingers 
subdomain regulates the de novo RdRP activity through 
participation in the formation of the active site and NTP 
entry channel, with motif F involved in binding to the nas-
cent base pair [82] and motif G involved in binding to RNA 
template [57]. All these motifs act in concert to form three 
tunnels, which ensure access to the template, the entrance 
Fig. 4  Structural analysis of ZIKV NS5–MTase domain. a Enzymatic 
reactions mediated by ZIKV NS5–MTase. b Ribbon representation 
of ZIKV NS5–MTase (PDB: 5TMH) bound to SAH. The Rossmann 
fold is colored in light pink, and the N- and C-terminal extensions are 
colored in slate. The SAH molecule is shown in ball-and-stick repre-
sentation. Ribbon (c) and surface electrostatic (d) representations of 
ZIKV NS5–MTase bound to both SAM and m7Gpp molecules (PDB 
5KQS). e Structural overlay of SAM- and m7Gpp-bound ZIKV NS5–
MTase (light pink, PDB 5KQS) and SAH- and m7G0pppAG-RNA-
bound DENV3 NS5–MTase (cyan, PDB 5DTO). f Close-up view of 
the interaction between ZIKV NS5–MTase and SAH (PDB 5TMH). 
The hydrogen bonds are depicted as dashed lines. g Close-up view of 
the interaction between ZIKV NS5–MTase and m7Gpp (PDB 5KQS). 
The color schemes in b, f and g are the same as in a 
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Fig. 5  Structural analysis of ZIKV NS5-RdRP domain. a A model 
for the conformational transition of ZIKV NS5-RdRP during dif-
ferent stages of RNA replication, highlighting the regulatory role 
of the priming loop (slate). The active site is marked by red aster-
isk. The template and synthesized RNA strands are colored in blue 
and purple, respectively. b Structural overview of the ZIKV NS5-
RdRP domain, with the N-terminal extension, Thumb, Fingers, Palm 
and Primer loop colored in orange, aquamarine, green, light pink 
and blue, respectively. The zinc ions are shown in purple spheres. 
c Structural overlay of ZIKV NS5-RdRP (wheat) and GTP-bound 
JEV NS5-RdRP (cyan), with the GTP binding sites highlighted in 
expanded view. The GTP-contact residues for JEV NS5-RdRP are 
labeled. The corresponding sites in ZIKV NS5-RdRP are labeled 
in parenthesis. The conserved motifs in ZIKV NS5-RdRP and JEV 
NS5-RdRP are colored in magenta and green, respectively. The GTP 
molecules are shown in stick representation. d Structural overlay 
of ZIKV NS5-RdRP (wheat, PDB 5TMH) and the replication ini-
tiation complex of HCV RdRP (green, PDB 4WTL), with the con-
served motifs in ZIKV RdRP colored in magenta. The RNA molecule 
bound to HCV is shown in stick representation, and the  Mn2+ ions are 
shown in salmon spheres. The potential repositioning of the priming 
loop of ZIKV NS5-RdRP during transition to the initiation state is 
indicated by a curved arrow. e, f Two expanded views of the HCV 
RdRP–RNA interaction. The RNA-contacting residues of HCV RdRP 
and their corresponding residues in ZIKV NS5-RdRP are colored in 
green and wheat, respectively. The hydrogen bonds are depicted as 
dashed lines. g Structural overlay of ZIKV NS5-RdRP (wheat, PDB 
5TMH) and the replication elongation complex of HCV RdRP (blue, 
PDB 4WTG), with the conserved motifs in ZIKV RdRP colored in 
magenta. The potential repositioning of the priming loop of ZIKV 
NS5-RdRP required for transition to the elongation state is indicated 
by a curved arrow
1730 B. Wang et al.
1 3
of the incoming ribonucleoside triphosphate (NTP), and the 
exit of the newly synthesized RNA products. Like its homo-
logues from JEV and DENV, the ZIKV NS5-RdRP contains 
two zinc ions, which might play a role in stabilizing the 
structural fold. Structural knowledge on the conformational 
transition of ZIKV NS5-RdRP between distinct replication 
states remains unavailable to date. Nevertheless, a structural 
comparison of ZIKV NS5-RdRP with the GTP-bound JEV 
RdRP [76], in which the GTP molecule partially occupies 
the space accommodating the first two nucleotides, sheds 
light onto the structural basis underlying the initial transi-
tion of ZIKV RdRP into a pre-initiation state (Fig. 5c). In 
essence, the priming loop of ZIKV NS5-RdRP appears to 
be in a position that is well poised for NTP recognition, with 
residues T796, W797 and S798 likely hydrogen bonded with 
the β,γ-phosphate groups of the initial NTP (Fig. 5c). By 
contrast, a large conformational adjustment is suggested for 
motif F, which would move toward the NTP molecule, with 
residues K462 and R473 interacting with the β-phosphate 
and base ring, respectively (Fig. 5c). In addition, recognition 
of the phosphate groups of the initial NTP may also involve 
residues R731 and R739 from the Thumb domain, recogni-
tion of the sugar group may involve D665 from motif C, 
and the base-specific recognition may involve residues D540 
from motif A and S603 from motif B.
Structural comparison of ZIKV NS5-RdRP with the rep-
lication initiation complex of HCV NS5, with a 5′-UACC 
RNA template, a 5′-pGG RNA primer and an incom-
ing UDP [74], provides further insights into the confor-
mational transitions of ZIKV NS5 toward the initiation 
state (Fig. 5d). Notably, motifs A, B and C from the palm 
domain of ZIKV NS5-RdRP are positioned similar to the 
corresponding region of HCV NS5, with residues D535, 
D540, S603, N612, D665 and D666 well poised to coor-
dinate  Mn2+ ions or interact with the incoming nucleotide 
for enzymatic catalysis (Fig. 5e). Motif F of ZIKV NS5-
RdRP is also well aligned with the corresponding region 
of HCV NS5 that interacts with the nascent Watson–Crick 
pair, likely involving residues K458 and R473 interacting 
with the incoming nucleotide and residues I475 and F477 
packing against the pairing residue (Fig. 5e, f). Meanwhile, 
motif E residue S712 and Thumb residues R731 and R739 
are positioned to donate hydrogen bonds to the backbone 
of the two primer nucleotides (Fig. 5e). On the other hand, 
it is apparent that the priming loop of ZIKV NS5-RdRP is 
positioned far deeper in the active site than the correspond-
ing region of HCV NS5 (Fig. 5d), implying that formation 
of the initiation complex would require the priming loop 
to retract from the active site to accommodate the grow-
ing RNA product. Interestingly, the corresponding region in 
HCV NS5 (residues Y448–S450) stacks against the 3′-end of 
the template RNA (Fig. 5f), implying that the priming loop 
of ZIKV NS5-RdRP may play a similar role in stabilizing 
the initiation complex. Structural comparison with the initia-
tion complex of HCV NS5 also supports the role of motifs B 
and G in escorting the template RNA, with motif B (residues 
G604–V606) making van der Waals contacts with sugar or 
base moieties of the template RNA and motif G (residues 
A408–A409) interacting with the backbone through main-
chain hydrogen bonding interactions (Fig. 5f). Finally, struc-
tural comparison of ZIKV NS5-RdRP with the replication 
elongation complex of HCV NS5 with a self-complimentary 
5′-CAA AAU UUU-3′ RNA duplex hints at additional con-
formational change of ZIKV NS5-RdRP accompanying the 
transition from the replication initiation state to the elonga-
tion state (Fig. 5g). Consistent with the current model [32] 
(Fig. 5a), this conformational rearrangement likely involves 
further retraction of the priming loop from the active site 
to accommodate the growing products of RNA synthesis.
Small molecule inhibitors for ZIKV NS5
The fact that viral NS5 is essential for viral replication but 
lacks a human counterpart makes NS5 an ideal drug tar-
get for potential therapeutics. In fact, the concept of NS5 
as a drug target has been validated by the success of com-
mercially available drugs targeting the viral polymerase of 
hepatitis C, which belongs to the same viral family as ZIKV 
[83]. Although there are currently no approved vaccines or 
antivirals for ZIKV disease, multiple strategies have been 
devised to develop inhibitors targeting ZIKV NS5 and its fla-
vivirus homologues. Consequently, a variety of agents have 
been synthesized and evaluated for potential therapeutics, 
and re-purposing of some patented drugs was also attempted 
[84–96].
ZIKV NS5‑RdRP inhibitors
ZIKV NS5-RdRP has been considered as a major drug tar-
get due to its virus-unique activity, which confers a poten-
tial advantage to development of inhibitors with fewer 
side effects [96–98]. In recent years, development of small 
nucleoside inhibitors (NIs) aiming to inhibit the activity of 
RdRP has proved to be a promising treatment approach [30, 
99, 100]. Acting as substrate analogs, incorporation of these 
compounds into nascent RNA could result in chain termi-
nation or lethal replication [30]. For instance, a hepatitis C 
virus NS5B polymerase nucleoside inhibitor named sofos-
buvir (Fig. 6a) was approved in the United States to cure the 
infection of hepatitis C virus, another member of the Fla-
viviridae family [101]. As a nucleotide analog, sofosbuvir 
could be metabolized to active triphosphate form and inhibit 
viral genome replication by performing as a chain termi-
nator [102, 103]. Recent studies further demonstrated that 
sofosbuvir antagonized ZIKV genome replication in human 
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cells in a concentration-dependent manner [89]. In addition, 
sofosbuvir treatment of ZIKV-infected mice deficient in type 
I IFN signaling pathway displayed higher survival rates than 
those of controls [89], which implied sofosbuvir might be 
a potential drug against ZIKV infection owing to its broad-
spectrum anti-Flaviviridae activity [84, 104].
The high structural resemblance of RdRPs among Fla-
viviridae members [105] prompted efforts to re-purpose 
other previously identified NS5-targeting inhibitors for 
ZIKV NS5. For instance, 7-deaza-2′-C-methyl adenosine 
(7DMA) (Fig. 6b), which was previously identified as a 
potent inhibitor for HCV [106] and other flaviviruses [107, 
108], exhibited consistent high potency against ZIKV in 
cell-based assays [88, 106, 109]. Likewise, another closely 
related NI, 2′-C-methyladenosine (2′CMA) (Fig. 6c), was 
also reported to reduce ZIKV infection pronouncedly [88]. 
A substitution of the 2′-C-methyl group for an ethynyl group 
further led to the generation of another candidate inhibitor, 
termed NITD008 (Fig. 6d), which exerted broad-spectrum 
antiviral effects on ZIKV, HCV and all the four serotypes 
of DENV [99]. Although direct pursuit of this inhibitor has 
been discontinued due to its toxicity in vivo [99], further 
modification of this inhibitor holds promise to yield an effec-
tive drug compound with less toxicity.
Fig. 6  Structures of a list of potential inhibitors against ZIKV NS5. Small molecule inhibitors targeting NS5-RdRP (a–g), NS5–MTase (h, i) and 
the NS5–NS3 interaction (j). Tr triphenylmethyl
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The combination of compound library screening with 
hit optimization has also led to discovery of an increasing 
number of antiviral inhibitors. For instance, a class of triph-
enylmethyl alkylated nucleoside analogs has been identified 
to antagonize DENV or YFV in vitro. Among them, the 
3′,5′-bis-O-tritylated-5-chlorouridine compound (Fig. 6e) 
generated promising results, and has been selected for future 
development [110]. Given that these lipophilic compounds 
exert their function via inhibition of RNA replication [110], 
it is possible to extend the investigation of this class of inhib-
itors toward ZIKV NS5-mediated RNA replication.
In addition to the direct substrate-binding sites, allosteric 
regulation sites have started to gain attention for develop-
ment of non-nucleoside inhibitors (NNIs) [111–113]. For 
instance, a fragment-based screening has recently led to the 
discovery of a cohort of NNIs targeting an allosteric pocket 
at the priming loop-proximate region of DENV NS5–RdRP, 
termed “N” pocket [112, 113]. In particular, two novel acyl-
sulfonamide derivatives (Fig. 6f, g) targeting this pocket 
show high potency in DENV1–4 NS5-mediated replica-
tion initiation, as well as moderately inhibit the replication 
elongation process [112]. Importantly, our recent structural 
analysis has indicated that the inhibitor binding site for these 
compounds is conserved in ZIKV NS5-RdRP [19], which 
provides a new platform for future development of inhibitors 
for ZIKV disease.
ZIKV NS5–MTase inhibitors
The RNA capping function of ZIKV NS5–MTase makes 
it another attractive target for antiviral development. Two 
non-selective competitive inhibitors, sinefungin (Fig. 6h) 
and SAH, were previously identified to impede both N7 
and 2′-O-methylation reactions of DENV NS5–MTase 
[114–116]. However, practical application of these two 
inhibitors is limited due to their cellular non-permeability 
and non-selectivity [105]. Later, structural characteriza-
tion of DENV3, WNV and ZIKV NS5–MTase further 
identified a conserved hydrophobic pocket located near 
the SAM-binding site, which paved the way toward the 
development of highly specific inhibitors [60, 117, 118]. 
It is worth noting that a recent effort has identified such 
a SAM-competitive inhibitor, NSC 12155, which shows 
inhibitory activity toward NS5–MTase from WNV, DENV-
2, DENV-3 and YFV in vitro, and high antiviral efficacy 
toward WNV, DENV-2 and JEV in cell-based assays [119]. 
It remains to be tested whether this compound also inhibits 
ZIKV. More recently, a high-resolution crystal structure of 
ZIKV NS5–MTase with a SAM analog (MS2042) (Fig. 6i) 
revealed that the 4-fluorophenyl moiety intruded into the 
RNA binding tunnel, suggesting that this compound might 
hinder the RNA methylation via occupation of the putative 
binding sites for the base and the 2′-OH groups of cap-0 
adenosine [120]. One of the major challenges of this class 
of SAM analogs faces is that they may lack target specific-
ity in cells, a recurring issues for all the NIs [99, 121]. The 
eukaryotic homologues of Flaviviridae NS5–MTase, such 
as DNA methyltransferases (DNMT) and RNA methyltrans-
ferases (RNMT), also use SAM as cofactors, thereby likely 
be non-specific targets of these compounds.
Potential inhibitors targeting the ZIKV NS5–NS3 
complex
It is worth noting that exploration of potential inhibitors 
targeting other biological functions of NS5 is also under-
way. Previous studies have identified an allosteric pocket 
(cavity B) on DENV NS5 critical to DENV RNA synthesis 
and the formation of active NS5–NS3 complex [97], which 
has led to development of an allosteric inhibitor, termed 16i 
(Fig. 6j), which is capable of disrupting the interaction of 
DENV NS5–NS3 under in vitro conditions [122]. Consid-
ering the high structural similarity between ZIKV NS5 and 
DENV NS5 (Fig. 3a), this compound could potentially be 
re-purposed to target ZIKV NS5. Due to lack of structural 
knowledge and comprehensive characterizations of the 
NS5–NS3 interactions, it remains unclear how NS5 and NS3 
cooperate in viral genome replication. Future structural and 
biochemical analyses of the ZIKV NS5–NS3 complex and 
their interactions with RNA will provide a novel framework 
for development of alternative antiviral therapeutic strategies 
against ZIKV.
Summary
The ZIKV NS5 protein plays a crucial role in genomic rep-
lication and RNA capping of ZIKV, as well as in interferon 
suppression. Recent progress in structural characterizations 
of ZIKV NS5 has provided an excellent opportunity for the 
development of inhibitors against ZIKV NS5. In particular, 
comparative structural analysis permits us to identify resi-
dues that are critical for different stages of ZIKV NS5-medi-
ated RNA replication. Based on the structural similarities 
between ZIKV NS5 and its homologues from flaviviruses, 
it has become an attractive strategy to develop ZIKV NS5 
inhibitors on the basis of the pool of small molecule inhibi-
tors that were previously identified for the NS5 proteins from 
other Flaviviridae viruses. Whereas this process is still in 
the early stages, many inhibitors have demonstrated strong 
inhibitory effects on NS5-RdRP-mediated RNA replica-
tion or MTase-mediated RNA capping activities. The major 
challenges in clinical application of these inhibitors include 
their often-unpredictable cellular toxicity and the emer-
gence of drug resistance. For instance, residues located in 
the catalytic or allosteric sites (e.g., “N” pocket) of the RdRP 
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domain, the N7 and 2′-O-methylation sites of the MTase 
domain, and the NS3-interacting sites of NS5 might gener-
ate potential resistance profiles, as what have been observed 
in other viral models [106, 112, 123, 124]. Conceivably, a 
combined use of drugs that target different sites or functional 
stages of ZIKV NS5 might offer a solution in overcoming 
these challenges.
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